Literature DB >> 24735470

The presence, function and regulation of IL-17 and Th17 cells in periodontitis.

Wan-Chien Cheng1, Francis J Hughes, Leonie S Taams.   

Abstract

Periodontitis (PD) is a chronic inflammatory disease characterised by tissue inflammation and destruction of the associated alveolar bone. It is caused by the colonisation of the bacterial plaque biofilm and the resultant host immune responses in the surrounding periodontal tissues. The pro-inflammatory cytokine IL-17, and IL-17 producing CD4+ T cells (also called Th17 cells) have been shown to play an important role in many inflammatory diseases. There is increasing evidence of the presence of IL-17 and Th17 cells in human PD lesions and this may be associated with disease severity. Moreover, several animal studies indicate the potential role of IL-17 and Th17 cells in gingival inflammation and the resultant bone destruction in PD. Here we review recent findings regarding the presence, function and regulation of IL-17 and Th17 cells in PD, and we highlight potential areas of future research interest.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Porphyromonas gingivalis; T helper 17 cells; interleukin-17; periodontal disease

Mesh:

Substances:

Year:  2014        PMID: 24735470     DOI: 10.1111/jcpe.12238

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  54 in total

1.  CD8+ Foxp3+ T Cells Affect Alveolar Bone Homeostasis via Modulating Tregs/Th17 During Induced Periodontitis: an Adoptive Transfer Experiment.

Authors:  Y K Han; Y Jin; Y B Miao; T Shi; X P Lin
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 2.  Revisiting the Page & Schroeder model: the good, the bad and the unknowns in the periodontal host response 40 years later.

Authors:  George Hajishengallis; Jonathan M Korostoff
Journal:  Periodontol 2000       Date:  2017-10       Impact factor: 7.589

3.  A20 Orchestrates Inflammatory Response in the Oral Mucosa through Restraining NF-κB Activity.

Authors:  Yajie Li; Erin C Mooney; Sara E Holden; Xia-Juan Xia; David J Cohen; Scott W Walsh; Averil Ma; Sinem E Sahingur
Journal:  J Immunol       Date:  2019-02-13       Impact factor: 5.422

4.  Gomisin N Decreases Inflammatory Cytokine Production in Human Periodontal Ligament Cells.

Authors:  Yoshitaka Hosokawa; Ikuko Hosokawa; Satoru Shindo; Kazumi Ozaki; Takashi Matsuo
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

Review 5.  Tissue-Specific Immunity at the Oral Mucosal Barrier.

Authors:  Niki M Moutsopoulos; Joanne E Konkel
Journal:  Trends Immunol       Date:  2017-09-08       Impact factor: 16.687

6.  Down-regulated Treg cells in exacerbated periodontal disease during pregnancy.

Authors:  Aislinn Hays; Xingyu Duan; Jianxin Zhu; Wei Zhou; Satya Upadhyayula; Juili Shivde; Li Song; Huizhi Wang; Li Su; Xuyu Zhou; Shuang Liang
Journal:  Int Immunopharmacol       Date:  2019-02-10       Impact factor: 4.932

Review 7.  Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis.

Authors:  George Hajishengallis; Triantafyllos Chavakis; Evlambia Hajishengallis; John D Lambris
Journal:  J Leukoc Biol       Date:  2014-12-29       Impact factor: 4.962

8.  Association of chronic periodontitis and type 2 diabetes mellitus with salivary Del-1 and IL-17 levels.

Authors:  Somil Saxena; Ranganath Venugopal; Rachana Chandrayan Rao; Monal B Yuwanati; Harshita Awasthi; Megha Jain
Journal:  J Oral Biol Craniofac Res       Date:  2020-08-19

Review 9.  Polymorphisms in interleukins 17A and 17F genes and periodontitis: results from a meta-analysis.

Authors:  Felipe Rodolfo Pereira da Silva; Larissa Dos Santos Pessoa; Any Carolina Cardoso Guimarães Vasconcelos; Weberson de Aquino Lima; Even Herlany Pereira Alves; Daniel Fernando Pereira Vasconcelos
Journal:  Mol Biol Rep       Date:  2017-10-13       Impact factor: 2.316

10.  The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.

Authors:  Erofili Papadopoulou; Ourania Nicolatou-Galitis; Ioannis Papassotiriou; Helena Linardou; Aikaterini Karagianni; Konstantinos Tsixlakis; Anthi Tarampikou; Kelly Michalakakou; Emmanouil Vardas; Dimitrios Bafaloukos
Journal:  Support Care Cancer       Date:  2019-04-17       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.